Medical Care

Global Targeted Drug BRAF Inhibitors for NSCLC Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for Targeted Drug BRAF Inhibitors for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drug BRAF Inhibitors for NSCLC.
The Targeted Drug BRAF Inhibitors for NSCLC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drug BRAF Inhibitors for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drug BRAF Inhibitors for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BeiGene
Novartis
Segment by Type
Dabrafenib
Trametinib
Lifirafenib
Others
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drug BRAF Inhibitors for NSCLC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Dabrafenib
1.2.3 Trametinib
1.2.4 Lifirafenib
1.2.5 Others
1.3 Market by Application
1.3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Perspective (2020-2031)
2.2 Global Targeted Drug BRAF Inhibitors for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drug BRAF Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug BRAF Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug BRAF Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug BRAF Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug BRAF Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Revenue (2020-2025)
3.1.2 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drug BRAF Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug BRAF Inhibitors for NSCLC Revenue in 2024
3.5 Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC Head office and Area Served
3.6 Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC, Product and Application
3.7 Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031)
5 Targeted Drug BRAF Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug BRAF Inhibitors for NSCLC Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2020-2031)
6.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025)
6.4 North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size (2020-2031)
7.2 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025)
7.4 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size (2020-2031)
9.2 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025)
9.4 Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BeiGene
11.1.1 BeiGene Company Details
11.1.2 BeiGene Business Overview
11.1.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.1.4 BeiGene Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025)
11.1.5 BeiGene Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025)
11.2.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Dabrafenib
Table 3. Key Players of Trametinib
Table 4. Key Players of Lifirafenib
Table 5. Key Players of Others
Table 6. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Region (2020-2025)
Table 10. Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Region (2026-2031)
Table 12. Targeted Drug BRAF Inhibitors for NSCLC Market Trends
Table 13. Targeted Drug BRAF Inhibitors for NSCLC Market Drivers
Table 14. Targeted Drug BRAF Inhibitors for NSCLC Market Challenges
Table 15. Targeted Drug BRAF Inhibitors for NSCLC Market Restraints
Table 16. Global Targeted Drug BRAF Inhibitors for NSCLC Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Players (2020-2025)
Table 18. Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug BRAF Inhibitors for NSCLC as of 2024)
Table 19. Ranking of Global Top Targeted Drug BRAF Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Targeted Drug BRAF Inhibitors for NSCLC Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC, Headquarters and Area Served
Table 22. Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC, Product and Application
Table 23. Global Key Players of Targeted Drug BRAF Inhibitors for NSCLC, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Type (2020-2025)
Table 27. Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Type (2026-2031)
Table 29. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Application (2020-2025)
Table 31. Global Targeted Drug BRAF Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Application (2026-2031)
Table 33. North America Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 48. BeiGene Company Details
Table 49. BeiGene Business Overview
Table 50. BeiGene Targeted Drug BRAF Inhibitors for NSCLC Product
Table 51. BeiGene Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 52. BeiGene Recent Development
Table 53. Novartis Company Details
Table 54. Novartis Business Overview
Table 55. Novartis Targeted Drug BRAF Inhibitors for NSCLC Product
Table 56. Novartis Revenue in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Research Programs/Design for This Report
Table 59. Key Data Information from Secondary Sources
Table 60. Key Data Information from Primary Sources
Table 61. Authors List of This Report


List of Figures
Figure 1. Targeted Drug BRAF Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Type: 2024 VS 2031
Figure 4. Dabrafenib Features
Figure 5. Trametinib Features
Figure 6. Lifirafenib Features
Figure 7. Others Features
Figure 8. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Application: 2024 VS 2031
Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 11. Adenocarcinoma of NSCLC Case Studies
Figure 12. Large Cell Carcinoma of NSCLC Case Studies
Figure 13. Targeted Drug BRAF Inhibitors for NSCLC Report Years Considered
Figure 14. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Targeted Drug BRAF Inhibitors for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Region: 2024 VS 2031
Figure 17. Global Targeted Drug BRAF Inhibitors for NSCLC Market Share by Players in 2024
Figure 18. Global Top Targeted Drug BRAF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug BRAF Inhibitors for NSCLC as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Targeted Drug BRAF Inhibitors for NSCLC Revenue in 2024
Figure 20. North America Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Targeted Drug BRAF Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 22. United States Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Targeted Drug BRAF Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 26. Germany Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Share by Region (2020-2031)
Figure 34. China Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Targeted Drug BRAF Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 42. Mexico Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 46. Turkey Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Targeted Drug BRAF Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. BeiGene Revenue Growth Rate in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025)
Figure 50. Novartis Revenue Growth Rate in Targeted Drug BRAF Inhibitors for NSCLC Business (2020-2025)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies